Articles related to IMMUNOTHERAPY

In patients with cisplatin-eligible muscle-invasive bladder cancer, perioperative enfortumab vedotin plus pembrolizumab improved event-free and overall survival compared with standard neoadjuvant gemcitabine-cisplatin chemotherapy in the phase 3 KEYNOTE-B15 trial.

Breast cancer remains the most prevalent cancer among U.S. women, with diagnoses and mortality projected to rise over the next two decades. Nurses play a central role in early recognition, patient education, treatment support, and ongoing surveillance throughout the care continuum.

An experimental cell therapy that couples a patient’s red blood cells with myelin protein fragments was well tolerated in a 10-patient Phase 1b study and was associated with increases in regulatory T-cells and reductions in neurofilament light chain, a biomarker linked to nerve injury.

An updated review of multiple myeloma management highlights revised high-risk definitions, anti-CD38-based quadruplet induction regimens, evolving maintenance strategies, and increasing use of CAR-T and bispecific immunotherapies across the disease continuum.

A multiplexed cytokine and tumor-antigen mRNA immunotherapy produced durable tumor responses in mouse models of pancreatic ductal adenocarcinoma, with approximately half of treated animals remaining disease-free for up to one year, although clinical relevance remains unproven.

Among 90 pediatric patients with relapsed or refractory B-cell precursor ALL, prior blinatumomab was associated with more relapses at atypical extramedullary sites. The retrospective single-center findings require prospective confirmation.